Clinical Trials with Cannabis Extract (Cannador®) at the IKF Berlin

1. CURRENT PROJECTS

   1. Randomized, double-blind, placebo-controlled phase-3 trial to determine the efficacy and safety of a standardized oral extract of Cannabis Sativa for the treatment of muscle stiffness and pain in Multiple Sclerosis: MUSEC (25-01)
      
      
2. COMPLETED PROJECTS
   
   1. Randomized, double-blind, placebo-controlled phase-3 trial to compare the efficacy of standardized cannbis extract and isolated Delta-9-THC on anorexia / cachexia in cancer patients (97-20)
      
   2. Monitoring of implementation ('Anwendungsbeobachtung') of Medical Grade Marihuana (Cannabis sativa) in the Netherlands (97-22)
      
   3. Randomised, placebo controlled, double-blind, crossover pilot study to evaluate the safety and tolerability of orally administered cannabinoids in patients with Multiple Sclerosis (98-11)
      
   4. Standardized survey to the medicinal use of cannabis products in the German-speaking area (98-17)
      
   5. Open-label, non-randomized phase-2 trial to determine the maximal tolerable dose (MTD) of standardized cannabis extract in the palliative treatment of cancer patients (99-09)
      
   6. Randomized, double-blind, placebo-controlled phase-2 study with cross-over design to determine tolerability, optimal dose and clinical effects of standardized cannabis extract in MS-induced spasticity (99-11)
      
   7. Randomized, double-blind, placebo-controlled cross-over trial for the treatment of herpes-zoster associated pain with a standardized cannabis extract (20-07)
      
   8. Randomized, double-blind, placebo-controlled phase-2 trial with cannabis extract in post-operative nausea and vomiting: PONV (21-01)
      
   9. Randomized, double-blind, placebo-controlled phase-3 trial of standardized cannabis extract and Delta-9-THC in Multiple Sclerosis:CAMS (21-04)
      
   10. Randomized, double-blind, placebo-controlled phase-1 trial to determine the pharmacokinetics of Delta-9-THC and metabolites and the influence of cannabis extract and THC on cognitive and neuro-physiologic parameters in healthy volunteers (21-06)
       
   11. Randomized, double-blind, placebo-controlled phase-1 trial to determine the analgesic effects of cannabis extract in experimentally induced hyperalgesia (22-01)
       
   12. Randomized, double-blind, placebo-controlled phase-2 study with cannabis-extract for levodopa-induced dyskinesia in Parkinson’s disease (23-03)
       
   13. Prospective, open-label, non-randomized study to determine the efficacy and safety of standardized cannabis extract in adjuvant pain management in cancer patients (23-09)
       
   14. Randomized, double-blind, placebo-controlled phase-2 study with a standardized cannabis extract in patients with Crohn´s disease (24-02)